Sandoz Group AG (SDZ.SW)
| Previous close | 32.18 |
| Open | 32.24 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 31.80 - 32.24 |
| 52-week range | 22.70 - 32.80 |
| Volume | |
| Avg. volume | 1,381,239 |
| Market cap | 13.71B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 199.31 |
| EPS (TTM) | 0.16 |
| Earnings date | N/A |
| Forward dividend & yield | 0.45 (1.41%) |
| Ex-dividend date | 03 May 2024 |
| 1y target est | 36.74 |
GlobeNewswireImproving access for patients: launch of Lisdexamfetamine further broadens Sandoz Canada portfolio
Michel Robidoux Michel Robidoux PrSandoz® Lisdexamfetamine, one of first generic equivalents of Vyvanse*, available on Canadian marketApproved for all indications of reference medicine: Attention Deficit Hyperactivity Disorder and Binge Eating Disorder in adultsPrSandoz® Amoxicillin, PrSandoz® Desvenlafaxine and PrSandoz® Riociguat also joined Sandoz Canada’s generics portfolio this spring BOUCHERVILLE, Quebec, June 05, 2024 (GLOBE NEWSWIRE) -- Sandoz Canada announced today the launch of PrSando
Globe NewswireSandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Wyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines Xgeva® and Prolia®EC approval based on robust development program confirming that biosimilar matches reference medicine in terms of safety, efficacy and qualityApproved for treatment of cancer-related bone disease and osteoporosis respectively Basel, May 22, 2024 – Sandoz, the global leader in gener
- Globe Newswire
Sandoz reports first quarter 2024 sales
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Strong first quarter performance, with net sales [1] of USD 2.5 billion, up 6% in constant currencies (up 5% in USD)Biosimilar business growing 21% in constant currencies All regions contributing to growthAcquisition of CIMERLI® (ranibizumab-eqrn) completed in March 2024 Basel, May 7, 2024 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, today announced net sales for the f
